315 related articles for article (PubMed ID: 19903374)
21. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
[TBL] [Abstract][Full Text] [Related]
22. The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
Li L; Yang G; Shi S; Yang M; Liu H; Boden G
Cytokine; 2009 Jan; 45(1):12-9. PubMed ID: 19026557
[TBL] [Abstract][Full Text] [Related]
23. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice.
Sasaki R; Nishimura N; Hoshino H; Isa Y; Kadowaki M; Ichi T; Tanaka A; Nishiumi S; Fukuda I; Ashida H; Horio F; Tsuda T
Biochem Pharmacol; 2007 Dec; 74(11):1619-27. PubMed ID: 17869225
[TBL] [Abstract][Full Text] [Related]
24. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
25. Rimonabant: more than an anti-obesity drug?
Costa B
Br J Pharmacol; 2007 Mar; 150(5):535-7. PubMed ID: 17245359
[TBL] [Abstract][Full Text] [Related]
26. EPA prevents fat mass expansion and metabolic disturbances in mice fed with a Western diet.
Pinel A; Pitois E; Rigaudiere JP; Jouve C; De Saint-Vincent S; Laillet B; Montaurier C; Huertas A; Morio B; Capel F
J Lipid Res; 2016 Aug; 57(8):1382-97. PubMed ID: 27307576
[TBL] [Abstract][Full Text] [Related]
27. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2008 Jun; 29(6):1036-41. PubMed ID: 18291559
[TBL] [Abstract][Full Text] [Related]
28. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
30. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways.
Watanabe T; Kubota N; Ohsugi M; Kubota T; Takamoto I; Iwabu M; Awazawa M; Katsuyama H; Hasegawa C; Tokuyama K; Moroi M; Sugi K; Yamauchi T; Noda T; Nagai R; Terauchi Y; Tobe K; Ueki K; Kadowaki T
J Biol Chem; 2009 Jan; 284(3):1803-12. PubMed ID: 19008231
[TBL] [Abstract][Full Text] [Related]
31. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
32. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
[TBL] [Abstract][Full Text] [Related]
34. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
35. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
[TBL] [Abstract][Full Text] [Related]
36. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
37. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
Gary-Bobo M; Elachouri G; Scatton B; Le Fur G; Oury-Donat F; Bensaid M
Mol Pharmacol; 2006 Feb; 69(2):471-8. PubMed ID: 16282221
[TBL] [Abstract][Full Text] [Related]
38. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Bensaid M; Gary-Bobo M; Esclangon A; Maffrand JP; Le Fur G; Oury-Donat F; Soubrié P
Mol Pharmacol; 2003 Apr; 63(4):908-14. PubMed ID: 12644592
[TBL] [Abstract][Full Text] [Related]
39. Platycodon grandiflorum modifies adipokines and the glucose uptake in high-fat diet in mice and L6 muscle cells.
Ahn YM; Kim SK; Kang JS; Lee BC
J Pharm Pharmacol; 2012 May; 64(5):697-704. PubMed ID: 22471365
[TBL] [Abstract][Full Text] [Related]
40. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
